Use of Home Telehealth Monitoring with Active Medication Therapy Management by Clinical Pharmacists in Veterans with Poorly Controlled Type 2 Diabetes Mellitus

2012 ◽  
Vol 32 (5) ◽  
pp. 420-426 ◽  
Author(s):  
Michael McFarland ◽  
Kristen Davis ◽  
Jessica Wallace ◽  
Jim Wan ◽  
Regina Cassidy ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Medication Therapy Management ◽  
Therapy Management ◽  
Clinical Pharmacists ◽  
Medication Therapy ◽  
Active Medication ◽  
Home Telehealth

scholarly journals EMDIA Case Series—Effective Medication Therapy Management (MTM) for Diabetes Type 2 Patients—A Proof of Concept Study

Pharmacy ◽  
2021 ◽  
Vol 9 (3) ◽  
pp. 137
Author(s):  
Maira Anna Deters ◽  
Emina Obarcanin ◽  
Holger Schwender ◽  
Stephanie Läer
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Blood Glucose ◽  
Pharmaceutical Care ◽  
Case Series ◽  
Medication Therapy Management ◽  
Therapy Management ◽  
Medication Therapy ◽  
Patients With Diabetes

Background: A 2016 meta-analysis of pharmaceutical care for patients with diabetes mellitus showed that the following four components were most effective: (a) individual goal setting, (b) sending feedback to the physician, (c) reviewing the medication, and (d) reviewing blood glucose measurements. Methods: To formulate a hypothesis regarding the effect of these four pharmaceutical care components on glycemic control in patients with diabetes mellitus and the feasibility of these components in practice. Ten patients with type 2 diabetes were included in the case series and received medication therapy management over four months. Results: The four care components were feasible in everyday practice and could be implemented within one patient visit. The average visits were 49 and 28 min at the beginning and end of the study, respectively. The glycated hemoglobin values did not change over the study period, though the fasting blood glucose decreased from 142 to 120 mg/dl, and the number of unsolved drug-related problems decreased from 6.9 to 1.9 per patient by the study end. Conclusions: This case series supports the hypothesis that community pharmacists can implement structured pharmaceutical care in everyday pharmacy practice for patients with type 2 diabetes mellitus.

Abstract 234: Treatment Satisfaction Levels among Adults with Concomitant Conditions of Type 2 Diabetes Mellitus and Hypertension

2012 ◽  
Vol 5 (suppl_1) ◽  
Author(s):  
Kathleen M Fox ◽  
Susan Grandy ◽  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Heart Disease ◽  
Side Effects ◽  
Diabetes Medication ◽  
Medication Therapy ◽  
The Us ◽  
Medication Side

Objective: This investigation evaluated the satisfaction with therapy for adults with the concomitant conditions of type 2 diabetes mellitus (T2DM) and hypertension (HTN). Methods: Respondents to the US S tudy to H elp I mprove E arly evaluation and management of risk factors L eading to D iabetes (SHIELD) 2009 survey reported their disease conditions, current medications, and satisfaction with therapy. Respondents reporting T2DM with concomitant HTN were identified. Current medications were catalogued, as respondents referred to their prescription bottles to record the name of each medication. Therapy satisfaction was captured with 3 separate questions as satisfaction/dissatisfaction with: 1) ability of the medication to prevent or treat your condition, 2) side effects of the medication, and 3) the medication overall; and scored using a 0 (completely dissatisfied) to 5 (completely satisfied) scale for heart disease treatment and diabetes treatment, separately. Scores of 0-2 were categorized as dissatisfied, score of 3 was neutral and scores 4-5 were satisfied. Results: A total of 911 adults with T2DM and HTN reported their satisfaction with therapy. For those who were dissatisfied with their diabetes medication (n = 63), 52.6% were also dissatisfied with their heart disease medication's ability to treat their HTN, 64.5% were dissatisfied with the side effects of their heart medications, and 61.9% were dissatisfied with their heart medication overall. For those who were dissatisfied with their heart disease medication (n = 59), 74.5% were also dissatisfied with their diabetes medication's ability to treat their diabetes, 56.6% were dissatisfied with the side effects of their diabetes medication, and 66.1% were dissatisfied with their diabetes medication overall. Conclusions: Although most respondents with T2DM and HTN were satisfied with their treatment, dissatisfaction with treatment for one condition was associated with therapy dissatisfaction in the other condition. Approximately 53%-65% of respondents who were dissatisfied with their diabetes medication were also dissatisfied with their HTN medication overall and in the ability to treat the condition and medication side effects.

scholarly journals Low Reported Adherence to the 2019 American Diabetes Association Nutrition Recommendations among Patients with Type 2 Diabetes Mellitus, Indicating the Need for Improved Nutrition Education and Diet Care

Nutrients ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3516
Author(s):  
Savvas Katsaridis ◽  
Maria G. Grammatikopoulou ◽  
Konstantinos Gkiouras ◽  
Christos Tzimos ◽  
Stefanos T. Papageorgiou ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Nutrition Education ◽  
American Diabetes Association ◽  
Compliance Rate ◽  
Multivariable Analysis ◽  
Adherence Rate ◽  
Medication Therapy

Patient adherence to guidelines is important for improved outcomes and prognosis. Nevertheless, many patients with type 2 diabetes mellitus (T2DM) do not comply with the recommendations regarding medication, physical activity, diet or self-care. The present cross-sectional study aimed to assess the level of adherence to the dietary recommendations issued by the American Diabetes Association (ADA) among patients with T2DM in Komotini, Greece. A total of 162 adults with T2DM (64.7 ± 10.6 years old), of which 41.4% were men, were recruited from the Sismanoglio Hospital and participated in the study. The level of adherence to individual recommendations issued by the ADA was assessed using yes/no questions. The overall adherence rate to the guidelines was low (41.2%). According to the multivariable analysis, age and medication therapy were identified as contributors to the compliance rate. No differences were noted in the total compliance rate between patients of different religious denominations (Muslims/Christians). Patients on oral antidiabetic agents (OAA) were more adherent compared with those on insulin therapy. A mere 3.7% of the participants had received nutrition education by a registered dietitian, 9.9% were following an individualized diet plan to improve glycemia, and 3.1% had set specific energy goals to reduce body weight. These findings are indicative of the need for the delivery of improved nutrition education.

scholarly journals A QUALITATIVE STUDY DISCOVERING THE COMMON MEDICATION-THERAPY PROBLEMS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN INDONESIA

2017 ◽  
Vol 10 (7) ◽  
pp. 246 ◽  
Author(s):  
Retno Wahyuningrum ◽  
Djoko Wahyono ◽  
Mustofa Mustofa ◽  
Yayi Suryo Prabandari
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Interpretative Phenomenological Analysis ◽  
Research Question ◽  
Face To Face ◽  
Medication Therapy ◽  
Lifestyle Choices ◽  
Index Value

Objective: Type 2 diabetes mellitus (T2DM) is a chronic and non-communicable diseases caused by insulin resistance. The management of the disease is not only carried out by administering pharmacological therapies, but also non-pharmacological. The aim of the overall study was to develop a model to improve the quality of counseling practice in pharmacies. The research question addressed in this substudy was to identify the medication therapy problems (MTPs) of T2DM.Methods: A total of 42 participants were interviewed between November 2015 and May 2016 through semi-structured surveys. Face-to-face interviews were conducted with patients who visited the internal clinic in the three general hospitals at Yogyakarta. It emphasized on the patient’s drug-related experiences, knowledge, perceptions, problems, and actions. The analysis was done thematically using the interpretative phenomenological analysis technique.Results: The average age of participants was 57.7 years, and more than half were women (55.5%). The most common therapy-related problems are related to individual factors, in term of inappropriate lifestyle choices, which include smoking, having a body mass index value over 25, lack of exercise, lack of knowledge about the nature of their disease, some did not know about the influence of foods on blood glucose level, the effect of the medicines on the disease and/or complications. The interviewees had realized that psychological stress enhanced their blood glucose.Conclusion: Pharmacists need to pay attention to the management of non-pharmacological when giving advice to patients with T2DM. 

scholarly journals Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus

2015 ◽  
Vol 8 ◽  
pp. CMED.S31526 ◽  
Author(s):  
Curtis Triplitt ◽  
Susan Cornell
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Sglt2 Inhibitor ◽  
Multidisciplinary Teams ◽  
Patient Centered ◽  
Clinical Pharmacists ◽  
Increased Risk ◽  
Clinical Benefits

Current guidelines for treatment of type 2 diabetes mellitus (T2DM) indicate a patient-centered approach that should go beyond glycemic control. Of the many antihyperglycemic agents available for treatment of T2DM, sodium-glucose cotransporter 2 (SGLT2) inhibitors offer the advantages of reduced glycated hemoglobin (A1C), body weight (BW), and systolic blood pressure (SBP) and are associated with a low risk of hypoglycemia when used either as monotherapy or with other agents not typically associated with increased risk of hypoglycemia. Collaborative, multidisciplinary teams are best suited to provide care to patients with diabetes, and clinical pharmacists can enhance the care provided by these teams. This review aims to provide insight into the mode of action, pharmacology, potential drug–drug interactions, clinical benefits, and safety considerations associated with use of the SGLT2 inhibitor canagliflozin in patients with T2DM and to provide information to enhance clinical pharmacists' understanding of canagliflozin.

scholarly journals Long-term patterns of adherence to medication therapy among patients with type 2 diabetes mellitus in Denmark: The importance of initiation

PLoS ONE ◽  
2017 ◽  
Vol 12 (6) ◽  
pp. e0179546 ◽  
Author(s):  
Majken Linnemann Jensen ◽  
Marit Eika Jørgensen ◽  
Ebba Holme Hansen ◽  
Lise Aagaard ◽  
Bendix Carstensen
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Medication Therapy ◽  
Adherence To Medication

scholarly journals Preventive pharmacotherapy of type 2 diabetes mellitus in patients with early carbohydrate metabolism disorders: long-term efficacy and clinical outcomes

2020 ◽  
Author(s):  
V.V. Boeva ◽  
A.N. Zavyalov
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Carbohydrate Metabolism ◽  
Lifestyle Modification ◽  
Term Therapy ◽  
Medication Therapy

Prevention of type 2 diabetes mellitus (T2DM) in prediabetic patients is a pressing concern due to its increasing prevalence. The aim of this study was to evaluate the efficacy of preventive pharmacotherapy in delaying progression of incident impaired glucose tolerance (IGT) and impaired fasting glycemia (IFG) to T2DM. The participants of the study (1,136 subjects) found healthy by a regular annual checkup underwent repeat screening for T2DM. Blood samples were processed following the guidelines for good preanalytical sample preparation. Patents with incident IGT/IFG were prescribed medication therapy with metformin or/and acarbose. The rate of IGT/IFG conversion to T2DM was evaluated in years 3 and 10 of observation. Carbohydrate metabolism disorders were detected in 18.5% (n = 210) of the re-screened patients: 5.0% had T2DM, 5.5% had IGT, 8.0% had IFG. Patients with incident T2DM were prescribed blood sugar lowering therapy and they were excluded from further analysis. Patients with IGT/IFG (n = 151) were given recommendations on lifestyle modification and prescribed metformin (77%) or a combination of metformin and acarbose (23%). Three years after the start of observation, the rate of conversion to T2DM was 6.8% in patients undergoing monotherapy with metformin and 11.4% in patients undergoing combination therapy with metformin and acarbose. After the active follow-up phase was over, the majority of the patients (n = 85) decided to discontinue preventive therapy without consulting their physicians. Ten years after the active follow-up phase, the rate of NGT/IFG conversion to T2DM was 38.8% in patients who had discontinued their treatment and 0% in patients still taking metformin (p < 0.01). Long-term therapy with metformin prevented progression to T2DM in the long run in 83.3% (p < 0.05).

Sign in / Sign up

Export Citation Format

Share Document